Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26474537 | 0.96 | MDM2 (0.46) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL17751673 | 0.95 | TLR2 (0.46) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL18161126 | 0.91 | TLR2 (0.43) | TLR2MDM2MDM4TP53PTPN1 | |
| SCHEMBL18161129 | 0.90 | TLR2 (0.44) | TLR2MDM2MDM4TP53PTPN1 | |
| SCHEMBL17760889 | 0.88 | TLR2 (0.46) | TLR2MDM2MDM4TP53TNF | |
| SCHEMBL15893676 | 0.85 | TLR2 (0.45) | TLR2MDM2MDM4TP53 | |
| SCHEMBL15761355 | 0.84 | MDM4 (0.44) | MDM2MDM4TP53PTPN1 | |
| SCHEMBL17751704 | 0.84 | MDM4 (0.43) | TLR2MDM2MDM4TP53PTPN1 | |
| SCHEMBL8242447 | 0.83 | MDM4 (0.43) | TLR2MDM2MDM4TP53 | |
| SCHEMBL31591662 | 0.83 | MDM2 (0.42) | TLR2MDM2MDM4TP53HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267719-A1 | METHOD FOR REGRESSING PANCREATIC TUMOR BY A LIPOSOMAL FORMULATION ALONG WITH DNA VACCINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267719-A1 | METHOD FOR REGRESSING PANCREATIC TUMOR BY A LIPOSOMAL FORMULATION ALONG WITH DNA VACCINES | PLEC, APLNR, CMKLR1 | TLR2 157/4885MDM2 1685/4885MDM4 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.